Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
- Wall St futures up as oil slips; telecoms pressured by SpaceX spectrum deal
- Oil falls as Trump comments on Iran talks ease supply concerns
- UBS flags level in gold prices where dip buyers will likely emerge
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- Investors need sustained Fed cuts to move cash off sidelines: BofA's Hartnett
| CYTOKINETICS (NASDAQ: CYTK) | Delayed: 62.01 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $62.01 | 52 Week High | $13.18 | |||
| Open | $62.01 | 52 Week Low | $6.00 | |||
| Day High | $62.01 | P/E | N/A | |||
| Day Low | $62.01 | EPS | $-1.24 | |||
| Volume | 352 | |||||
| REPROS THERAPEUTICS (NASDAQ: RPRX) | Delayed: 56.21 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $56.21 | 52 Week High | $3.48 | |||
| Open | $56.21 | 52 Week Low | $0.80 | |||
| Day High | $56.21 | P/E | N/A | |||
| Day Low | $56.21 | EPS | $-1.54 | |||
| Volume | 5,691 | |||||
